This subgroup analysis assessing secondary prophylaxis for Pneumocystis carinii pneumonia (PCP) describes a multicenter, open-labeled, randomized, controlled trial evaluating the discontinuation of PCP prophylaxis. The main inclusion criterion was a history of PCP and an increase in the CD4 cell count to 1200 cells/mL associated with receipt of highly active antiretroviral therapy for у3 months. The primary end point was the development of definitive or presumptive PCP. A total of 146 patients were enrolled (77 in the treatment discontinuation arm). After 12 years, 1 definitive and 1 presumptive case of PCP were observed, both of which occurred in patients who discontinued therapy. In most patients, secondary prophylaxis for PCP can be safely discontinued after potent antiretroviral therapy is initiated, but the threshold of 1200 CD4 cells/mL may not be considered absolutely safe. Patients who present with symptoms after discontinuation of secondary prophylaxis should be evaluated for PCP despite high CD4 count and complete virus suppression.
2], presumably as a result of the improvement of the immune system. Even in persons with extremely severe immunodeficiency, the CD4 cell count often increases to more than the level considered at risk for the development of opportunistic infections.
Many observational studies and randomized controlled trials [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] have been conducted to evaluate whether this CD4 cell recovery can protect against several opportunistic infections. Three previous studies (1 randomized study and 2 observational studies) demonstrated that discontinuing secondary prophylaxis for Pneumocystis carinii pneumonia (PCP) in persons treated with HAART was safe [9, 10, 12] . The main limitations of these studies were (1) that they could not detect a CD4 cell count threshold greater than which it is safe to discontinue prophylactic regimens, and (2) they had short periods of observation. The aim of this randomized study is to evaluate the long-term safety of discontinuation of secondary prophylaxis for PCP.
PATIENTS AND METHODS
The Changes in Opportunistic Prophylaxis (CIOP) Study was designed as an open-label, randomized, controlled trial. Persons undergoing primary prophylaxis for PCP and toxoplasmic encephalitis began to be enrolled in the study in January 1998 [8] ; persons receiving secondary prophylaxis for PCP began to be enrolled in June 1998. Trial participants were enrolled at 41 clinical centers located throughout Italy. Determination of CD4 cell count and plasma virus level was performed at each site. Lymphocyte subpopulations were measured at all centers by 3-color flow cytometry. HIV RNA levels were determined with use of either a PCR assay (Amplicor HIV-1 Monitor Assay; Roche Molecular Systems) or a branched-chain DNA assay (Chiron). Until the end of 1999, all clinical centers used techniques with a lower limit of detection of 400 copies/mL and 500 copies/mL for PCR and branched-chain DNA assay, respectively; after that date, all clinical centers used ultrasensitive tests with respective lower limits of detection of 20 copies/mL and 50 copies/mL. All data analyses were performed at the trial's coordinating center (Clinic of Infectious and Tropical Diseases, University of Modena and Reggio Emilia, Modena, Italy).
Inclusion and exclusion criteria. To be included in the study, individuals were required to be HIV seropositive, to be 118 years old, to have a CD4 count of !200 cells/mL at time of initiation of HAART, to have recovered from a confirmed or presumptive episode of PCP, and to be undergoing one of the following regimens of secondary prophylaxis against PCP: trimethoprim-sulfamethoxazole, aerosolized pentamidine, atovaquone, dapsone alone, or dapsone plus pyrimethamine.
Participants also had to be receiving HAART, defined as a combination of у3 antiretroviral agents, including nucleoside reverse-transcriptase inhibitors plus protease inhibitor and/or one nonnucleoside reverse-transcriptase inhibitor. Furthermore, the CD4 cell count had to have increased to 1200 cells/ mL on 2 consecutive measurements obtained у1 month apart in the 3 months before enrollment. Virus load was not an eligibility criterion. Patients who did not fulfill inclusion criteria were excluded from the study, as were those with a previous episode of toxoplasmic encephalitis. The study was approved by each local ethics committee. All eligible persons had to read and sign an informed consent form.
Randomization.
Upon enrollment onto the study, the clinical centers recorded demographic data, dates of previous episodes of PCP, history of prophylaxis against PCP, and history of antiretroviral therapy. This information was sent to the coordinating center, which confirmed that participants fulfilled the inclusion criteria. Within 24 h of receiving this information, the coordinating center randomized participants to 1 of the following 2 study arms: patients who would discontinue secondary prophylaxis against PCP (hereafter referred to as "the discontinuation arm") and those who would continue prophylaxis (hereafter referred to as "the continuation arm"). The ratio of participants between the 2 arms was 1:1. To reduce potential unbalance among clinical centers, there was a block size every 8 enrolled patients per center [19] . Physical examinations, routine blood control, and CD4 cell count measurements were performed every 2 months; plasma HIV load was measured at least every 4 months. Those participants randomized to the discontinuation arm whose CD4 cell count decreased to р200 cells/mL (measured twice, 1 month apart) during the study period were offered to reinitiate prophylaxis and continued to be observed for the entire duration of the study.
End points. The primary end points of the study were a confirmed or a presumptive diagnosis of PCP or death related to this opportunistic infection. The criteria used for a confirmed diagnosis of PCP were the detection of P. carinii cysts (by immunofluorescence) in induced sputum samples and/or bronchoalveolar lavage fluid specimens, or histologic demonstration of microorganisms in transbronchial or open-lung samples obtained by biopsy. The diagnosis of extrapulmonary pneumocystosis was based on the identification of P. carinii in histological or cytological material obtained from extrapulmonary sites.
Presumptive diagnosis was based on the presence of exertional dyspnea and nonproductive cough, bilateral diffuse infiltrates noted on a chest radiograph, abnormal arterial blood gas levels, and unequivocal response to anti-P. carinii therapy in the absence of another diagnosis. The secondary end points consisted of death not related to the primary end points, other HIV infection-related events (i.e., stage B and C events from the Centers for Disease Control and Prevention HIV classification), a CD4 count of р200 cells/mL, and events not related to HIV infection. Data regarding side effects and changes in prophylactic regimens and antiretroviral therapy were recorded every 2 months.
Every 6 months, the coordinating center sent clinical monitors to the participating clinical centers to ensure that participants were being selected properly and that accurate data were being provided. The clinical centers were required to report suspected diagnoses of a primary end point to the coordinating center р24 h after occurrence.
Statistical analysis. On the basis of pre-HAART data, we assumed that PCP would develop in 15% of patients receiving secondary prophylaxis during the first year of follow-up and in 60% of those who discontinued prophylaxis [20] . We esti- mated that у30 patients at risk would be needed in each treatment group to permit us to detect a 45% difference with 90% certainty and a 5% significance level. An analysis was performed that used the intent-to-treat principle. To compare demographic, clinical, virologic, and immunologic characteristics between the 2 treatment arms at enrollment, we used the x 2 test or the Wilcoxon rank-sum test, depending on whether the variable was categorical or continuous. The length of followup was calculated as the time that elapsed between the date of randomization and the date of either diagnosis of PCP, death, the first measurement of a CD4 cell count of р200 cells/mL, or the end of the study, depending on which occurred first. We calculated exact 95% CIs and P values to compare the 2 groups for the incidence of the end points, having assumed that the events followed a Poisson distribution.
RESULTS

Characteristics of the study participants at enrollment.
From June 1998 through December 1999, 146 persons were enrolled in the study; 77 were randomized to the discontinuation arm, and 69 were randomized to the continuation arm. Epidemiological characteristics of and immunological and virological values for patients in the 2 groups at the time of initiation of HAART and at the time of study entry are shown in table 1. The secondary prophylactic regimens, the diagnosis of the first episode of PCP, and the median time from PCP diagnosis to the first measurement of a CD4 cell count of 1200 cells/mL are shown in table 2.
The median durations of secondary prophylaxis before enrollment were 26.6 months in the discontinuation arm and person-years) for participants in the continuation arm. Two cases of PCP (1 definitive case and 1 presumptive case) were diagnosed among the 146 participants during the study period; both cases occurred in the discontinuation arm. Patient 1. Patient 1 had a definitive diagnosis of PCP. The patient was a 40-year-old man who initiated secondary prophylaxis for PCP in April 1996 with daily doses of trimethoprim-sulfamethoxazole. In October 1997, he began receiving HAART that included indinavir plus 2 nucleoside reversetranscriptase inhibitors, and, in November 1998, his CD4 cell count increased to 1200 cells/mL (341 cells/mL). In February 2000, when he had a CD4 cell count of 407 cells/mL and a virus load of !20 copies/mL, he was randomized to the discontinuation arm. In April 2000, when he had a CD4 cell count of 339 cells/mL (14%) and a plasma HIV load of !20 copies/mL, the patient presented with high fever, cough, and shortness of breath. Chest radiography revealed bilateral interstitial and reticulomicronodular infiltrates. Indirect immunofluorescence examination of induced sputum samples revealed P. carinii cysts. The patient was treated with trimethoprim-sulfamethoxazole for 3 weeks, with resolution of the clinical and radiological findings.
Patient 2. Patient 2 had a presumptive diagnosis of PCP. The patient was a 38-year-old man who initiated secondary prophylaxis for PCP in April 1997 with daily doses of trimethoprim-sulfamethoxazole and HAART (zidovudine, lamivudine, and indinavir). In June 1999, after 18 months in which he continually had a CD4 cell count of 1200 cells/mL, the patient was randomized to the discontinuation arm of the study; at this time, his CD4 count was 300 cells/mL and his virus load was !400 copies/mL. In February 2000, he was treated with intravenously administered corticosteroids for asthma; 1 month later, when he had a CD4 cell count of 357 cells/mL (16%) and a plasma HIV load of !400 copies/mL, he presented with high fever, cough, and shortness of breath. The arterial PO 2 level was 59 mm Hg, and the lactic acid dehydrogenase level was 697 UI/L. Chest radiography revealed bilateral interstitial and reticulomicronodular infiltrates. Neither examination of an induced sputum sample nor culture of a bronchoalveolar lavage sample revealed P. carinii or other pulmonary pathogens. Invasive procedures (i.e., transbronchial biopsy and open-lung biopsy) were not performed. On the basis of clinical evolution and radiological presentation, the patient was treated with tri- Immunologic and virologic time trends during the followup period. CD4 cell counts and virus loads at the time of study entry are shown in table 1. A small but significant difference was found in CD4 cell count, and plasma virus loads were similar. During the follow-up period, no differences were present between the 2 groups as far as CD4 cell count and plasma virus load are concerned (data not shown). The CD4 cell count decreased to р200 cells/mL on 2 consecutive measurements in only 3 participants (2 in the discontinuation arm and 1 in the continuation arm); these participants were withdrawn from the study but remained in the analysis.
DISCUSSION
Three previous studies (2 observational studies and 1 randomized study) have been published suggesting the safety of discontinuing secondary PCP prophylaxis in HIV-infected persons whose CD4 cell counts have increased to 1200 cells/mL after the initiation of HAART [9, 10, 12] . Our study has 2 major differences: the period of observation is longer, and 2 events were recorded. Actually, the present study shows that, in patients who discontinue secondary PCP prophylaxis, a recurrent episode of PCP is possible even when the CD4 cell count is ation of PCP prophylaxis. It is noteworthy that all studies concerning either primary or secondary PCP prophylaxis, including ours, failed to determine a CD4 cell threshold above which it could be considered safe to discontinue the prophylactic regimens.
In a study of patients with a first episode of PCP, Kaplan et al. [21] showed that patients with a CD4 cell count of !250 cells/mL and a CD4 cell percentage of !14% were at higher risk than were those with a CD4 cell count of !200 cells/mL or a history of thrush or fever; as a consequence, they suggested changing the criteria for primary PCP prophylaxis. The present study shows that, even if these criteria are considered, it could have been suggested that both patients could discontinue prophylactic regimens. In fact, the 2 events happened in patients who had CD4 cell counts of 1250 cells/mL, and only one of these events occurred in the presence of a CD4 cell percentage of 14%. For these reasons, and because there was a lack of information about the CD4 cell percentage for all of the other participants, our study does not provide any indication regarding the threshold CD4 cell percentage or absolute CD4 cell count at which it could be considered safe to discontinue prophylactic regimens.
It is noteworthy that recurrent episodes of PCP occurring 16 months after the first episode, as occurred in our patients, may not represent reactivations of latent infections but may in fact be reinfections [22] [23] [24] [25] . Moreover, in one patient, the use of systemic corticosteroids could have favored the development of PCP [26] . This randomized, controlled trial allowed us to draw some conclusions. First, despite the presence of 2 PCP episodes, the incidence of events in this study was extremely low, suggesting that it is indeed safe to discontinue secondary prophylaxis for PCP. Second, a close monitoring of CD4 cell values should be performed, and PCP prophylaxis should be reinitiated when the CD4 cell count decreases to р200 cells/mL. Furthermore, in our opinion, in the presence of previously described risk factors, such as receipt of systemic glucocorticoids treatment or antineoplastic chemotherapy, clinicians should consider reinitiation of PCP prophylaxis independent of the CD4 cell count. Clinicians should keep in mind patient history regarding opportunistic infections, nadir CD4 cell count, and discontinuation of prophylactic regimens and maintenance therapies. In any case, patients who present with respiratory symptoms after discontinuing secondary prophylaxis should be closely evaluated for PCP even in the presence of CD4 cell counts of 1200 cells/mL and complete virus load suppression.
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